Recent updates on CAR T clinical trials for multiple myeloma

Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies have dramatically changed the natural history of multiple myeloma (MM). However, most patients eventually suffer a relapse and succumb to the disease. Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer 2019-11, Vol.18 (1), p.154-154, Article 154
Hauptverfasser:	Lin, Quande, Zhao, Juanjuan, Song, Yongping, Liu, Delong
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antigens Antigens, CD19 - immunology Antigens, Neoplasm - immunology B cell maturation antigen B cells B-Cell Maturation Antigen - antagonists & inhibitors B-Cell Maturation Antigen - immunology B-Cell Maturation Antigen - metabolism BCMA CAR T Chimeric antigen receptor Clinical trials Clinical Trials as Topic Combined Modality Therapy - methods Humans Immunotherapy, Adoptive - methods Monoclonal antibodies Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - immunology Multiple Myeloma - therapy Receptors, Antigen, T-Cell - genetics Receptors, Antigen, T-Cell - metabolism Receptors, Chimeric Antigen - genetics Receptors, Chimeric Antigen - metabolism Review Stem cells T cells T-Lymphocytes - immunology T-Lymphocytes - metabolism Transplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies have dramatically changed the natural history of multiple myeloma (MM). However, most patients eventually suffer a relapse and succumb to the disease. Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturation antigen (BCMA), CD138, CS1 glycoprotein antigen (SLAMF7) and light chains are in active development for therapy of refractory /relapsed (RR) MM. CD19- targeted CAR T cells in conjunction with autologous stem cell transplantation also showed activity in RRMM. Dual- target CAR T cells are in clinical trials for RRMM. This review summarized the recent updates of ongoing CAR T clinical trials for multiple myeloma.
ISSN:	1476-4598 1476-4598
DOI:	10.1186/s12943-019-1092-1